HUTCHMED (China) HMDCF
NASDAQ HMDCF
$2.16 +0.00 (+0.00%)
At close: Sep 8, 2026 · 4:00 PM EDT

HUTCHMED (China) (HMDCF) EBITDA Margin Growth (3y) (2018 - 2021)

Analysis

HUTCHMED (China) (HMDCF) EBITDA Margin Growth (3y) (2018 - 2021) Analysis & Trends

Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) EBITDA Margin Growth (3y) (Qtr)
1 Amgen 211.37 Bn 197.38 Bn 7.24 Bn -347.00
2 Gilead Sciences 181.12 Bn 177.94 Bn 6.22 Bn -15,844.00
3 Vertex Pharmaceuticals 132.11 Bn 124.26 Bn 2.84 Bn -377.00
4 Regeneron Pharmaceuticals 82.51 Bn 74.52 Bn 3.93 Bn -204.00
5 Argenx Se 61.69 Bn 56.50 Bn 1.37 Bn 7,045.00
6 Moderna 54.62 Bn 49.48 Bn 52.00 Mn -1,934.00
7 Alnylam Pharmaceuticals 34.14 Bn 30.84 Bn 992.69 Mn 9,003.00
8 Biogen 31.29 Bn 30.01 Bn 1.96 Bn -2,825.00
9 Roivant Sciences 30.09 Bn 30.09 Bn 1.16 Mn -2.41 Mn
10 HUTCHMED (China) 376.85 Mn 391.04 Mn - -
Historic Data

Historic Data

Download Data
DateValue
Dec 31, 2021 13,116.00
Sep 28, 2021 31,447.00
Jun 30, 2021 -26,157.00
Mar 31, 2021 32,653.00
Jun 30, 2019 -24,390.00
Jun 30, 2018 13,576.00